Purpose. The role of concurrent use of proton-pump inhibitors (PPIs) in the outcomes of treatment for Clostridium difficile colitis was studied. Methods. The records of inpatients at a large Veterans Affairs medical center in whom C. difficile colitis was diagnosed between June 2004 and July 2005 were retrospectively reviewed. Data collected included patient characteristics at baseline, antibiotic therapy prescribed before and during therapy for C. difficile colitis, concurrent treatment with a PPI, response to therapy for C. difficile colitis, and recurrence of the disease in the 90 days after symptoms resolved. Outcomes of therapy were classified as cures, treatment failures, or disease recurrences. Results. A total of 140 patients (138 men and 2 women) were included in the study. Ninety-seven (69%) of patients received a PPI and 43 (31%) did not. Of patients receiving a PPI, 37 (38%) were cured of C. difficile colitis, 20 (21%) did not respond to therapy, and 40 (41%) had disease recurrence. Among the non-PPI patients, 27 (63%) were cured, 9 (21%) did not respond, and 7 (16%) had recurrence. Patients receiving PPIs were 4.17 times as likely to have recurrence as their counterparts who did not. Conclusion. PPI therapy was associated with an increased risk of recurrent C. difficile colitis.
C
lostridium difficile colitis is an increasingly common complication of medical therapy.
The principal cause appears to be disruption of the normal intestinal flora, resulting in acquisition and overgrowth of C. difficile. This organism produces one or more toxins that cause colonic inflammation, leading in extreme cases to necrosis with perforation. 1 Traditional treatments, including oral metronidazole and vancomycin, were originally proven efficacious decades ago and remain the standard of care. [2] [3] [4] [5] The incidence and severity of C. difficile colitis have increased, as have the rates of treatment failure and disease recurrence. 6, 7 The reasons for this are attributed in part to increased use of broad-spectrum antibiotics, the presence in hospitals of patients who are older and sicker than in the past, and the emergence of more virulent strains of C. difficile. 6, 8 Gastric acidity is a nonspecific mechanism that protects the host against ingested pathogens. Because C. difficile is transmitted by ingestion, the possible link between C. difficile colitis and gastric acid suppression has been investigated. Medications that suppress gastric acid, the most potent being proton-pump inhibitors (PPIs), have been associated with microbial colonization of the normally sterile upper gastrointestinal tract, with altered gastrointestinal flora and increased susceptibility Am J Health-Syst Pharm-Vol 64 Nov 15, 2007 to infectious gastroenteritis. 9 Such medications have specifically been associated with a greater likelihood of C. difficile colitis. [10] [11] [12] [13] [14] [15] The risk increases when the use of PPIs is associated with administration of antibiotics or antineoplastic drugs, advanced age, an immunocompromised state, long hospitalizations, gastrointestinal surgery or manipulation, or exposure to C. difficile. [10] [11] [12] To our knowledge, no study has examined the role of PPIs in the outcomes of treatment for C. difficile colitis. We sought to determine whether concurrent use of PPIs predisposes patients to treatment failure in C. difficile colitis or to recurrence following therapy.
Methods
Data for our study were obtained by review of electronic patient medical records from the Michael E. DeBakey Veterans Affairs Medical Center. These records document every contact between a patient and the medical center, including all health care providers' notes from inpatient stays, outpatient visits, or telephone calls and all information relating to prescriptions. The study looked at all patients who were diagnosed with C. difficile colitis on the basis of typical symptoms, including diarrhea, abdominal pain, fever, leukocytosis, and a positive enzyme-linked immunosorbent assay (ELISA) result for C. difficile Data collected included patient characteristics at baseline, antimicrobial agents prescribed before and during therapy for C. difficile colitis, indication for and duration of PPI therapy during the same period, specific therapy for the C. difficile infection, time to resolution of symptoms, and recurrence of disease in the 90 days after symptoms resolved. By hospital policy, initial treatment was with oral metronidazole 1-2 g/day for 10-14 days. During the study period, 42 patients received nitazoxanide 500 mg p.o. twice daily for 7 or 10 days as part of a doubleblind randomized study comparing metronidazole with nitazoxanide; the remaining 98 patients received metronidazole for at least 10 days. 16 During the period under study there were consistent efforts to contain the spread of C. difficile but no changes in infection-control policies or in the physical arrangement of beds, toilets, or equipment.
Outcomes of therapy were classified as cures, treatment failures, or disease recurrences. 6, 17 Patients were regarded as cured when their signs and symptoms of C. difficile colitis fully resolved during treatment and did not recur in the ensuing 90 days. Treatment failure was defined as the persistence of signs and symptoms for ≥10 days after the beginning of treatment. Recurrence was defined as the complete resolution of signs and symptoms during treatment followed by their return, with a positive ELISA finding for C. difficile toxins A and B, within 90 days after the end of the therapy. Patients were not included in the study if they failed to complete at least 7 days of treatment or if they had a gastrointestinal condition associated with diarrhea (e.g., inflammatory bowel disease) or that precluded the ability to assess diarrhea (e.g., a colostomy).
PPI use was defined as seven or more days of PPI treatment before C. difficile colitis was diagnosed and continuous use thereafter. By hospital policy, the only PPI in use during the study period was omeprazole. Eleven patients were receiving concurrent therapy with a histamine H 2 -receptor antagonist and a PPI.
We used Stata statistical software (StataCorp LP, College Station, TX) for group comparisons by analysis of variance (ANOVA) and for determining the risk ratio for disease recurrence. In addition, we used 3 × 2 contingency tables to assess statistical significance with Fisher's exact test (a = 0.05).
This study was approved by the institutional review board of Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center.
Results
Patients. A total of 140 patients who received a full course of therapy for C. difficile colitis were included in the study. There were 138 men and 2 women (reflecting the veteran population), and the mean ± S.D. age was 67 ± 13 years. Of the 140 patients, 64 (46%) were cured, 29 (21%) failed to respond to therapy, and 47 (34%) had disease recurrence-outcomes remarkably similar to those reported for our hospital in 2003-04. Characteristics of patients. The mean ages for patients who were cured, who did not respond to treatment, and who had recurrent disease were 68, 70, and 65 years, respectively. The differences were not significant by ANOVA (p = 0.173) or by Bonferroni-adjusted multiple comparison between any two groups (p > 0.2) ( Table 1) .
Underlying diseases, such as malignancy, diabetes, and renal insufficiency, were common. There was a suggestion of a higher rate of cancer in the failure group (p = 0.078); otherwise, these underlying conditions were distributed similarly among the three groups of patients (p > 0.07, Fisher's exact test). Altered mental status was more common in patients who were cured than in the other two groups (p = 0.002).
Effect of PPIs. Of the 140 patients, 97 (69%) received a PPI for seven or more days (PPI group) and 43 (31%) did not (non-PPI group). Of the PPI-group members, 37 (38%) were cured of C. difficile colitis, 20 (21%) did not respond to therapy, Am J Health-Syst Pharm-Vol 64 Nov 15, 2007 and 40 (41%) had disease recurrence. Among the non-PPI patients, 27 (63%) were cured, 9 (21%) did not respond, and 7 (16%) had recurrence. With 3 × 2 contingency tables used to compare the rates of cure, recurrence, and treatment failure between the PPI and non-PPI groups, Fisher's exact test indicated a significant difference among the three patient groups (p = 0.007). Since the proportion of patients who failed therapy was identical in the PPI and non-PPI groups, those patients were not included in calculating the odds ratio for recurrent disease in patients taking PPIs compared with those not taking PPIs (4.17 [95% confidence interval, 1.66-10.38] p = 0.0032, Fisher's exact test).
Indication for PPIs. The medical records documented an indication for PPI use for only 50 (52%) of the 97 patients who were taking PPIs. In those cases for which documentation was available, indications for use of PPIs were similar among treatment groups. The major cause was listed as "prophylaxis" (30 [60%] of the 50 cases). Table 2 summarizes antibiotic use during the 14 days preceding diagnosis of C. difficile colitis. Twelve patients (9%) received no prior antibiotics. The mean numbers of antibiotics used to treat patients who were cured, those who did not respond, and those with recurrent disease were 2.48, 1.90, and 2.68, respectively. The differences were not significant by ANOVA (p = 0.13) or by Bonferroniadjusted multiple comparison between any two groups (p > 0.145). The distribution of antibiotic use in these patients mirrored antibiotic use throughout our medical center during the period under study, except that clindamycin and vancomycin appeared to be disproportionately represented.
Antibiotic use.

Discussion
We reviewed the association of PPIs with outcomes of therapy for C. difficile colitis at a Veterans Affairs medical center. Patients who received PPIs had the same probability of failing to therapy (21%) as those who did not but were 4.17 times as likely to have a recurrence within 90 days as those who did not receive PPIs. Earlier studies have shown that the risk of contracting C. difficile colitis is greater in patients who are taking PPIs than in those who are not. [10] [11] [12] [13] [14] [15] To our knowledge, this study is the first to examine the impact of PPIs on the outcome of treatment for this disease.
Agents that modify and suppress gastric acid are thought to increase susceptibility to gastrointestinal infection by eliminating the acid barrier that normally destroys most potentially infective organisms. 11 This mechanism would explain the increased likelihood of infection with C. difficile, since most such infections are thought to arise from new exposures rather than from the proliferation of preexisting, colonizing organisms. A link to recurrent infection is less apparent. Perhaps exposure to organisms that have persisted in the environment is responsible. 18 In that scenario, treatment eradicates the infecting organisms in the bowel, but the patient is exposed to, and becomes infected by, organisms that (7) 12 (9) 98 (70) Table 1 . Treatment failure was defined as the persistence of signs and symptoms for >10 days after the beginning of treatment. c Recurrence was defined as the complete resolution of signs and symptoms during treatment followed by their return, with a positive finding for C. difficile toxins A and B (by enzyme-linked immunosorbent assay), within 90 days after the end of therapy.
Baseline Characteristics of Patients with
he or she sheds into the environment. A limitation of our study is that we did not do stool cultures and therefore could not carry out a molecular analysis of C. difficile isolates from our patients; thus, we are unable to comment further on this point. Other limitations include the study of patients at only one medical center that treats mainly middle-aged and older men and the possible confounding effect of attempts to limit the hospitalwide outbreak of C. difficile infection that were in progress during the study period. Finally, PPIs were prescribed for continuous use, but actual compliance could not be verified beyond pharmacy-order or prescription-refill data.
Many of the patients did not meet our medical center's criteria for use of PPIs. A trend toward more casual prescribing of PPIs may be contributing to the increase in incidence of C. difficile colitis and the increase in treatment failure. Considering that clinically significant gastrointestinal bleeding occurs in only 1-4% of critically ill patients and that PPIs may predispose patients to C. difficile colitis recurrence and treatment failure, further analysis of the risks and benefits of these medications appears warranted.
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Conclusion
PPI therapy was associated with an increased risk of recurrent C. difficile colitis. 
